Incidence of endocrine and exocrine insufficiency in patients with autoimmune pancreatitis at diagnosis and after treatment: a systematic review and meta-analysis

• Published in: European journal of internal medicine Vol. 100; pp. 83 - 93
• Main Authors: Lanzillotta, Marco, Tacelli, Matteo, Falconi, Massimo, Arcidiacono, Paolo Giorgio, Capurso, Gabriele, Della-Torre, Emanuel
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.06.2022
• Subjects: Autoimmune Diseases - complications; Autoimmune Diseases - drug therapy; Autoimmune Diseases - epidemiology; Autoimmune Pancreatitis; Autoimmune pancreatitis – diabetes mellitus –Pancreatic exocrine insufficiency; Diabetes Mellitus - epidemiology; Humans; Incidence; Meta-analysis; Pancreatitis - complications; Prevalence; Autoimmune pancreatitis – diabetes mellitus –Pancreatic exocrine insufficiency; Meta-analysis
• ISSN: 0953-6205; 1879-0828
• DOI: 10.1016/j.ejim.2022.03.014

•DM and PEI affect one third and half of patients with AIP at diagnosis respectively.•DM and PEI are more frequent in type 1 AIP compared to type 2 AIP.•Treatment with GCs increases the risk of developing DM in AIP patients. Autoimmune pancreatitis (AIP) is a rare form of pancreatitis that may lead to endocrine and exocrine insufficiency if left untreated. AIP clinically responds to glucocorticoids (GCs) therapy, but multiple GCs courses are often required to maintain remission with detrimental effects on glycaemic control. In this systematic review and meta-analysis, we aimed to assess the rate of endocrine and of exocrine insufficiency at diagnosis and at follow up in patients with AIP as well as the impact of GC therapy on pancreatic function in the long-term. The MEDLINE, SCOPUS, and EMBASE databases were searched from inception to August 2021 to identify studies reporting data on endocrine and exocrine insufficiency in patients with AIP. Pooled events were calculated using a random-effect model and expressed in terms of pooled prevalence rates. A total of 6522 AIP patients and sixty-two studies were included in the analysis. The pooled estimate rate for the overall prevalence of diabetes in AIP at baseline was 37% (95% CI 32-42, I2 96%). The pooled prevalence rate of exocrine insufficiency was 45% (95%CI 32.9-57.4; I2 97%). The pooled estimate rate of diabetes at follow-up was 44% (95%CI 26.1-62.4) in studies where GCs were given to 100% of patients and 42% (95%CI 30.6-52.9) in studies where GCs were given to less than 100% of patients. A large proportion of patients with AIP displays concomitant exocrine and endocrine insufficiency at the time of diagnosis. The incidence of diabetes at the longest available follow up tends to increase in patients treated with GCs.